Apogee Therapeutics Inc (APGE)Healthcare | Biotechnology | San Francisco, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 7:14 a.m. UTC
The immediate outlook is neutral due to a lack of statistical data to confirm momentum, despite the stock hitting fresh highs recently. However, the long-term investment case is effectively zero because the company is burning significant cash with negative free cash flow and operating cash flow, while posting negative returns on both assets and equity. The negative forward earnings estimates indicate that the business is not yet generating sustainable profits, and the absence of any price history prevents an assessment of whether the market has already priced in these risks. Furthermore, there is no dividend distribution to provide any income cushion. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.572 |
| Market Cap | 10,223,142,912 |
| Forward P/E | -26.00 |
| Beta | 0.33 |
| Website | https://www.apogeetherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.6644058 |
| Address1 | One Letterman Drive |
| Address2 | Building B Suites B6-850 and B6-800 The Presidio of San Francisco |
| All Time High | 135.09 |
| All Time Low | 14.19 |
| Ask | 171.87 |
| Ask Size | 200 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,428,202 |
| Average Volume | 2,953,556 |
| Average Volume10Days | 1,428,202 |
| Beta | 0.327 |
| Bid | 96.59 |
| Bid Size | 200 |
| Board Risk | 5 |
| Book Value | 15.914 |
| City | San Francisco |
| Compensation Risk | 8 |
| Country | United States |
| Currency | USD |
| Current Price | 135.07 |
| Current Ratio | 26.439 |
| Date Short Interest | 1,786,665,600 |
| Day High | 135.09 |
| Day Low | 135.06 |
| Debt To Equity | 0.572 |
| Ebitda | -322,120,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -28.627 |
| Enterprise Value | 9,221,257,216 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 134.1818 |
| Fifty Two Week High | 135.09 |
| Fifty Two Week Low | 35.39 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 58,441,609 |
| Forward Eps | -5.19587 |
| Forward P E | -25.995647 |
| Free Cashflow | -145,624,624 |
| Full Time Employees | 261 |
| Fullday Change | 135.07 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 135.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,788,220,800 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.02315 |
| Held Percent Institutions | 1.10805 |
| Implied Shares Outstanding | 75,687,735 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc. |
| Long Name | Apogee Therapeutics Inc |
| Market Cap | 10,223,142,912 |
| Max Age | 86,400 |
| Message Board Id | finmb_1816591253 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -294,372,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,223,142,365 |
| Number Of Analyst Opinions | 5 |
| Open | 135.06 |
| Operating Cashflow | -243,894,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | (650) 394-5230 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 8.487496 |
| Profit Margins | 0.0 |
| Quick Ratio | 26.167 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.71429 |
| Regular Market Day High | 135.09 |
| Regular Market Day Low | 135.06 |
| Regular Market Open | 135.06 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 0 |
| Return On Assets | -0.20299 |
| Return On Equity | -0.32456002 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 62,201,093 |
| Shares Percent Shares Out | 0.056500003 |
| Shares Short | 4,273,438 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,133,296 |
| Short Name | Apogee Therapeutics, Inc. |
| Short Percent Of Float | 0.0728 |
| Short Ratio | 3.63 |
| State | CA |
| Symbol | APGE |
| Target High Price | 135.11 |
| Target Low Price | 133.0 |
| Target Mean Price | 134.622 |
| Target Median Price | 135.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 971,926,016 |
| Total Cash Per Share | 12.888 |
| Total Debt | 6,833,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -4.34 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 93.117676 |
| Underlying Symbol | APGE |
| Uuid | a31551ee-fb27-3439-a3c7-bbfae7df46cb |
| Volume | 0 |
| Website | https://www.apogeetherapeutics.com |
| Zip | 94,129-1492 |